ENA Respiratory Raises $22.4M in Series B to Advance Antiviral Host Defense Programs

Deal Summary

ENA Respiratory, a Melbourne clinical-stage pharmaceutical company developing antiviral host defense enhancers, secured $22.4M (AUD34M) in a Series B round led by existing and new backers to advance its clinical programs. Investors include the Gates Foundation, Flu Lab, Brandon Capital, Uniseed and Stoic Venture Capital.